Loring Wolcott & Coolidge Fiduciary Advisors LLP Cogent Biosciences, Inc. Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.1 Billion
- Q3 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 1,000 shares of COGT stock, worth $9,080. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$9,080% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COGT
# of Institutions
171Shares Held
113MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$95.1 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$83.9 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$68.5 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$66.2 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$63.2 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $597M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...